Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MyoKardia, Inc.
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.
US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
- In Vitro Diagnostics
Drug Discovery Tools